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Abstract: Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) 
have provided new alternatives for minimally invasive treatment of gastrointestinal adenomas 
and early-stage cancers that involve a minimum risk of lymph-node metastasis. The use of 
submucosal injections is essential to the success of these endoscopic resection techniques. 
The “ideal” submucosal injection solution should provide a sufﬁ  ciently high submucosal ﬂ  uid 
cushion for safe and effective EMRs and ESDs while also preserving lesion tissue for accurate 
histopathological assessment. In the past, normal saline (NS) solution was commonly used for 
this purpose, but it is difﬁ  cult to achieve the proper submucosal elevation and maintain the 
desired height with NS. Therefore, other safe and effective facilitative submucosal injection 
solutions have been developed that also take into account relevant cost-beneﬁ  t considerations. 
This review examines recent advances in the development of effective submucosal injection 
solutions for use during endoscopic resections.
Keywords: submucosal injection solution, endoscopic mucosal resection (EMR), endoscopic 
submucosal dissection (ESD), gastrointestinal tract
Introduction
Endoscopic mucosal resection (EMR) is a minimally invasive technique which is safe, 
relatively simple, and effective in the curative treatment of early cancers with an extremely 
low risk of lymph-node metastasis and for the removal of adenomas as precursors to cancer 
in the gastrointestinal region. EMR also plays an important role in the assessment of 
resected specimens for accurate pathological staging (Kudo 1993; Soetikno et al 2003).
In contrast to polypectomy, EMR involves the lifting up of a lesion from the 
muscular layer by injecting a ﬂ  uid agent, commonly normal saline (NS) solution, 
into the submucosal layer. Because it is difﬁ  cult to achieve the necessary submucosal 
elevation and then maintain the desired height with NS, various submucosal injection 
solutions have been newly developed for safer, easier to use, and more effective EMRs 
(Torii et al 1995; Yamamoto et al 1999, 2002, 2003; Conio et al 2002; Sumiyoshi et al 
2002; Feitoza et al 2003; Fujishiro et al 2004a, 2004b, 2005, 2006; Lee et al 2004, 
2006; Rajan et al 2004; Uraoka et al 2005; Jin Hyun et al 2006; Katsinelos et al 2006; 
Yamasaki et al 2006; Ishizuka et al 2007).
This review examines recent advances in the development of effective submucosal 
injection solutions for use during endoscopic resections.
Endoscopic resection techniques
EMR
EMR is a less invasive curative treatment for gastrointestinal adenomas and early-stage 
cancers that involve a minimum risk of lymph-node metastasis. It is also useful Drug Design, Development and Therapy 2008:2 132
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for obtaining specimens for accurate histopathological 
staging to determine the risk of lymph-node metastasis. 
EMR completely removes the affected mucosa by excis-
ing through the middle or deeper portion of the gut wall 
submucosa. Various EMR techniques have been described 
and four methods involving snare resection are commonly 
used: (1) the inject and cut method (Kudo 1993; Soetikno 
et al 2003; Uraoka et al 2005); (2) the inject, lift, and cut 
method (Karita et al 1991; Tada et al 1993); (3) cap-assisted 
EMR (EMRC) (Inoue et al 1993; Matsuzaki et al 2003); and 
(4) EMR with ligation (EMRL) (Suzuki et al 1999).
The inject and cut technique, also known as submucosal 
injection polypectomy, has become widely used in recent 
years because of its simplicity. The diseased mucosa is 
lifted up from the muscular layer by creating a submucosal 
ﬂ  uid cushion, captured, strangulated using an electrosurgical 
snare, and then resected. However, injection into the thin 
submucosal layer is a delicate process, the injected solution 
tends to dissipate quickly, ﬂ  at and depressed lesions are hard 
to capture with the snare compared with protruded lesions, 
and large or awkwardly located lesions can be difﬁ  cult to 
remove.
The technical limitations of standard EMR techniques, 
therefore, often result in piecemeal resections, particularly 
in cases of large lesions or those in less accessible locations, 
leading to problems in correctly assessing the depth of tumor 
invasion and increasing the possibility of local recurrence. 
Consequently, en-bloc resections using this procedure are 
limited to lesions approximately 15–20 mm in size (Tanaka 
et al 2001; Uraoka et al 2005; Gotoda 2005).
Endoscopic submucosal dissection
Endoscopic submucosal dissection (ESD), a relatively new 
endoscopic resection procedure, was developed speciﬁ  cally 
for removing larger lesions (Ohkuwa et al 2001; Ono et al 
2001; Yamamoto et al 2003; Gotoda 2005; Saito et al 2005, 
2007; Fujishiro et al 2006; Uraoka et al 2007). Lesions 
are dissected directly along the submucosal layer using an 
electrosurgical knife, resulting in an en-bloc resection of 
even large lesions.
ESD has been predicted to replace conventional surgery 
in treating certain cancerous stages, but because it has a 
higher rate of perforation and bleeding complications than 
conventional EMR, a greater degree of endoscopic skill and 
experience is required than for EMR. Various submucosal 
injection solutions had previously been developed and shown 
to be satisfactory for use during EMR, but introduction of the 
lengthier ESD procedure required a longer-lasting solution 
to help identify the cutting line during dissection of the 
submucosal layer.
Role of submucosal injection solution
Various recently developed endoscopic techniques, 
submucosal injection solutions, and devices such as the elec-
trosurgical snare, submucosal injection catheter, and endo-clip 
have made EMR safer, easier, and more effective (Yamano 
et al 2004; Taku et al 2007). The use of submucosal injection 
is essential for a successful EMR, as injection of ﬂ  uid into the 
submucosa cushions and isolates the tissue just before capture 
of the target lesion with a snare, thereby reducing thermal 
injury and the risk of perforation and hemorrhage while also 
facilitating an en-bloc resection. The en-bloc resection, in turn, 
provides for more accurate histopathological assessment and 
reduces the risk of local recurrence after the EMR, as previ-
ously described (Ono et al 2001; Soetikno et al 2003).
Submucosal injection is considered to play an important 
role in the EMR procedure, and the ‘‘ideal’’ submucosal 
injection solution should be both long-lasting and produce a 
hemispheric shape to facilitate snaring. In addition, providing 
a sufﬁ  ciently high submucosal elevation is important for safe 
submucosal cutting during the ESD procedure.
NS solution has been commonly used for this purpose, but 
it is difﬁ  cult to produce the proper submucosal ﬂ  uid cushion 
and maintain the desired height, particularly for ﬂ  at elevated 
lesions, because of the rapid absorption of NS into the surround-
ing tissue (Yamamoto et al 1999; Conio et al 2002; Sumiyoshi 
et al 2002; Fujishiro et al 2004; Jin Hyun et al 2006; Katsinelos 
et al 2006; Lee et al 2006). Several studies, therefore, have 
compared various submucosal injection solutions by evaluating 
their ability to maintain mucosal elevation during EMR.
In general, hypertonic solutions create higher mucosal 
elevation than NS solution (Conio et al 2002; Fujishiro et al 
2004, 2006; Katsinelos et al 2006). Solutions currently used 
besides NS for submucosal injections including hypertonic 
saline, hypertonic dextrose water (DW) (Katsinelos et al 
2006), glycerol (Torii et al 1995; Sumiyoshi et al 2002; 
Uraoka et al 2005), and hyaluronic acid (HA) (Fujishiro et al 
2004; Yamamoto et al 1999, 2002, 2003) are listed in Table 
1. Submucosal injection solutions need to be evaluated not 
only for their lesion-lifting ability during EMR and ESD 
procedures, but they also must be safe, avoid histopathologi-
cal tissue damage, and be of reasonable cost.
Submucosal injection solutions
Although NS solution is safe, inexpensive, and commonly 
used throughout the world, there are problems in achieving Drug Design, Development and Therapy 2008:2 133
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a suitable submucosal elevation and then maintaining the 
desired height with NS. A better submucosal injection solution 
is needed, therefore, so that safer, easier, and more effective 
EMRs can be performed, and a number of alternatives have 
been developed recently in response to this need.
Glycerol
Glycerol (Glyceol®, Chugai Pharmaceutical Co, Tokyo, 
Japan) is a hypertonic solution consisting of 10% glycerin 
and 5% fructose in an NS solution that has been used 
intravenously to treat cerebral edema with no toxic systemic 
effects (Takeuchi et al 1989; Sakamaki et al 2003). Glycerol 
was ﬁ  rst mentioned as a submucosal injection solution in 
a report on 24 early gastric cancer cases that were treated 
using the EMRC method; however, no investigation was 
carried out on the efﬁ  cacy of this particular solution at that 
time (Torii et al 1995). Subsequently, we directed our atten-
tion to glycerol and carried out basic and clinical studies 
on its effectiveness as a submucosal injection solution 
(Sumiyoshi et al 2002; Uraoka et al 2005).
Basic study
In an in vitro study, the abilities were compared of glycerol 
and NS solution to maintain long-lasting submucosal elevation 
using fresh resected human colon specimens (Sumiyoshi et al 
2002). Each solution was injected into the submucosal layer 
using a 23-gauge submucosal injection needle with a clear 
endoscopic attachment, 16 mm in diameter, to a submucosal 
elevation height of 5 mm; 10 separate test solution submucosal 
injections were made in both the glycerol and NS groups. 
Submucosal elevations were observed from the lateral position 
and recorded using a measuring device 1, 3, 5, 7, and 10 min-
utes after injection. The glycerol group maintained a signiﬁ  -
cantly longer-lasting submucosal elevation than the NS group 
(Figures 1 and 2) and the hemispheric shape produced by the 
glycerol solution facilitated snaring satisfactorily (Figure 2).
Clinical study
During the next stage, we examined clinically the efﬁ  cacy of 
glycerol as a submucosal solution during EMR (Uraoka et al 
2005). This study retrospectively compared the en-bloc resec-
tion and complete resection rates as well as the rates of associ-
ated complications for the EMR of large ﬂ  at lesions, known 
as laterally spreading tumors (LSTs) (Saito et al 2001; Tanaka 
et al 2001; Uraoka et al 2005, 2006), in the colorectum when 
using glycerol or NS as the injecting solution. The en-bloc 
resection rate was 63.6% (70/110) in the glycerol group and 
48.9% (55/113) in the NS group (p = 0.03) (Table 2). Based on 
lesion size, there was no difference between the two groups for 
lesions  20 mm, but the glycerol group had a higher en-bloc 
resection rate than the NS control group (p   0.01) in LSTs 
measuring 10–19 mm. LSTs  20 mm are technically more 
difﬁ  cult to remove en bloc by conventional EMR techniques 
(Tanaka et al 2001; Gotoda 2005) and the use of glycerol 
did not improve the en-bloc resection rate for such lesions. 
The rate of associated complications such as perforations and 
delayed bleeding was similar in both groups. There were no 
problems involving histopathological tissue damage to the 
resected specimens due to the injection solution in either 
group. The use of glycerol was shown to safely increase en-
bloc resections in this study. Because glycerol is relatively 
inexpensive in Japan (US $0.01–0.02/mL) and readily avail-
able, it is considered superior to NS for use as a submucosal 
injection solution for EMRs of colorectal tumors.
Dextrose water
Dextrose water (DW) is a hypertonic solution that produces 
a higher submucosal elevation than NS solution. DW is 
inexpensive and readily available, but Fujishiro and colleagues 
(2005) reported that possible histopathological tissue dam-
age resulted when the dextrose concentration was  15% in 
a comparison study of injection solutions consisting of just 
NS, DW with ﬁ  ve different concentrations (5%, 10%, 15%, 
30%, and 40%) of dextrose, glycerol, and HA using mini-pig 
stomachs. Considerable tissue damage was observed with DW 
at concentrations  20% which could adversely affect resected 
EMR specimens and ulcer healing.
Table 1 Submucosal injection solutions for EMR/ESD
Normal Saline (NS) 
Solution
–   Commonly used, but ﬂ  uid cushion 
not long-lasting
Hypertonic Saline Solution –    Hypertonic solution
Glycerol3,11,12 –   Facilitates easier and safer EMR/
ESD at low cost
Dextrose Water (DW)10 –   Cheaper hypertonic solution, 
but likelihood of tissue damage 
in concentrations  20%
Hyaluronic Acid (HA)4–6,13,14 –   Produces and maintains 
long-lasting ﬂ  uid cushion, but high 
cost and limited availability
Fibrinogen Mixture (FM)15,16 –   High viscosity and reasonable 
cost, but risk of virus transmission
Hydroxypropyl 
Methylcellulose (HPMC)17–19
–   Produces long-lasting ﬂ  uid 
cushion, inexpensive and readily 
available, but detailed toxicity 
testing necessary
Abbreviations: EMR, endoscopic mucosal resection; ESD, endoscopic submucosal 
resection.Drug Design, Development and Therapy 2008:2 134
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Figure 1 Chronological changes in submucosal elevations after injections of glycerol and normal saline (Sumiyoshi et al 2002). Glycerol maintained a signiﬁ  cantly longer-lasting 
submucosal elevation than normal saline.
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Clinical use of a 50% DW plus epinephrine submucosal 
injection solution (Katsinelos et al 2006) has also been 
reported, but subsequent evidence of histopathological 
tissue damage raises a serious question about the suitability 
of DW. In fact, it has been used in the past as a sclerosing 
agent in esophageal varices (Yamamoto et al 1999). The 
histopathological predictive factor of lymph-node metastasis 
in early stage gastrointestinal cancer has been clariﬁ  ed so 
that accurate histopathological assessment is critical for 
determining the appropriate therapeutic strategies. Use of 
Glycerol Normal Saline
Immediately
3 Minutes
5 Minutes
7 Minutes
Figure 2 Changes in submucosal elevation immediately, and 3, 5, and 7 minutes after injection of glycerol and normal saline.   The hemispheric shape produced by glycerol 
solution facilitated successful snaring (Sumiyoshi et al 2002).Drug Design, Development and Therapy 2008:2 135
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DW with concentrations  20% is not recommended due to 
the likelihood of histopathological tissue damage.
Hyaluronic acid
Hyaluronic acid (HA) is a type of glycosaminoglycan 
found in connective tissue. It has a high viscosity and water 
retention capability without being antigenic or toxic to 
humans (Nagano et al 1984). Approved indications for its use 
in clinical practice in many countries are for intra-articular 
injections for osteoarthritis and eye surgery. Recently, a 
0.4% solution of HA has been approved for commercial use 
as a submucosal solution (MucoUp®, Johnson and Johnson 
Medical Co., Tokyo, Japan) in Japan. HA has provided the 
longest-lasting ﬂ  uid cushion (Yamamoto et al 1999, 2002, 
2003; Fujishiro et al 2006), and higher successful en-bloc 
resection and lower perforation complication rates have 
been reported using HA, particularly for colorectal ESD 
(Yamamoto et al 2003; Saito et al 2005, 2007; Fujishiro et al 
2006; Uraoka et al 2007). HA is considered to be the best 
agent for submucosal injections; however, its disadvantages 
are high cost (US $49.50–128.00/mL in the United States) 
and unavailability. In addition, the lack of Food and Drug 
Administration approval has limited its use in the United 
States, and stimulation in the growth of residual tumor cells 
has been indicated due to an enhancement in both tumor 
growth and CD44 expression of cancer cells at wound sites 
in murine models (Matsui et al 2004). HA is considered to 
be suitable, therefore, for ESD because of its higher en-bloc 
resection rate even for larger lesions, but not for endoscopic 
piecemeal resection procedures that have an increased risk 
of residual tumors.
Hyaluronic acid mixture
Fujishiro and colleagues (2004) investigated the possibility of 
a suitable lower-cost HA solution by varying the molecular 
weight of HA and mixing it with various solutions. The 
viscoelastic properties of HA can be changed using different 
molecules and mixing it with other solutions. Based on 
their results, a mixture of higher-molecular-weight HA and 
a sugar solution with or without glycerin is regarded as a 
more cost-effective submucosal ﬂ  uid cushion option than 
conventional HA.
In further considering the issue of histopathological tis-
sue damage, a mixture of HA and glycerol was found to be a 
better solution than a mixture of HA and DW, and there are, 
in fact, many reports of its use in colorectal ESDs (Saito et al 
2005, 2007; Fujishiro et al 2006; Uraoka et al 2007).
Fibrinogen mixture
Fibrinogen mixture (FM) solution has a high viscosity and 
produces a long-lasting submucosal elevation (Lee et al 
2004). It also helps keep the visual ﬁ  eld clear after EMR 
by providing a microvascular hemostatic effect. Lee and 
colleagues (2006) conducted a prospective randomized 
study of the efﬁ  cacy of FM compared with NS solution in 
conventional gastric EMRs after their preliminary examina-
tion conﬁ  rmed the initial efﬁ  cacy and safety of this solution 
(Lee et al 2004). Although there were no differences in 
en-bloc and complete resection rates, FM resulted in fewer 
injections and shorter procedure times. Subsequently, it has 
been primarily used in the ESD of larger lesions in Korea 
because of the longer-lasting submucosal ﬂ  uid cushion, clear 
visual ﬁ  eld after EMR, and reasonable cost (US $0.2/mL) 
(Lee et al 2006).
Because ﬁ  brinogen is produced by the fractionalization 
of coagulation proteins in human serum, contamination with 
hepatitis or other viruses is possible; the risk of transmission 
of such viruses could pose a problem. If this issue can be 
resolved, however, FM could become a very useful solu-
tion in performing EMRs and ESDs due to its reasonable 
cost compared with other viscous agents, in addition to its 
hemostatic capability.
Hydroxypropyl methylcellulose
Hydroxypropyl methylcellulose (HPMC), a cellulose 
derivative with viscoelastic properties, is primarily used 
by ophthalmologists in Western countries for creating 
artiﬁ  cial tears (Ravalico et al 1997). It is also known to be 
stable when coming in contact with blood or a catheter at 
room temperature. A preliminary study on living porcine 
esophagus performed by a group in Rochester, Minnesota, 
showed long-lasting submucosal ﬂ  uid cushion with minimal 
tissue reaction (Feitoza et al 2003). In another group study, 
Normal Saline
Glycerol 85.9%
(61/71)
66.7%
(46/69)
10–19 mm 
23.1%
(9/39)
20.5%
(9/44)
20–29 mm 
#p < 0.01; 
63.6%
(70/110)
48.7%
(55/113)
Total
*
Notes: *p = 0.03;
#  §
§ p = 0.79. 
Table 2 Comparison of en-bloc resection rates based on lesion 
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NS, 0.1% HA, 0.3% HPMC, 2% FM, and 20% mannitol were 
compared for their submucosal elevation durations as well as 
the physical and chemical properties of each solution using a 
fresh transverse colon specimen from a mongrel model (Jin 
Hyun et al 2006). The submucosal elevation lasted longer 
with HA, HPMC, and FM than with mannitol or NS. Subse-
quently, the same Minnesota group successfully performed a 
novel EMR technique using HPMC for the removal of large 
areas of mucosa in pig models (Rajan et al 2004).
HPMC is less expensive than HA (0.83% HPMC costs 
US $0.15/mL as a generic product in the United States) and 
is readily available in the United States. The major difference 
between the two solutions is that HA exists in the connective 
tissue of mammals and is not antigenic while HPMC is a 
synthetic product that could potentially give rise to antigenic 
reactions (Fujishiro et al 2004). More detailed toxicity testing 
in appropriate animal models will be necessary, therefore, 
before HPMC is ready to be used for medical applications 
on patients.
Carboxymethylcellulose
Carboxymethylcellulose (CMC) is used in the food science 
and pharmaceutical industries as a viscosity modiﬁ  er or 
thickener. It has high viscosity and is reported to be nontoxic 
and generally nonallergenic (Fredericks et al 1986). An in 
vitro study in which a submucosal ﬂ  uid cushion was created 
by injection of CMC solution using porcine stomach speci-
mens (Burns et al 1997) demonstrated that it was possible 
to dissect the submucosal layer from the muscular layer as 
a result of higher viscosity at a CMC solution concentration 
greater than 2.0%. Subsequently, submucosal injection of a 
2.5% CMC solution was assessed to be satisfactory for use, 
as ESD procedures in living pig models resulted in en-bloc 
resections of three specimens without any procedure-related 
complications. In addition, histopathological examina-
tions revealed no tissue damage of the muscular layer and 
surrounding mucosal tissue. Because a CMC solution with 
a concentration greater than 2% is very viscous, a special 
18G submucosal injection needle catheter was required to 
minimize injection resistance, as was a special hood attach-
ment with a Teﬂ  on tube to insert the larger needle catheter. 
As with HPMC, further study on the safety and efﬁ  cacy of 
CMC is necessary before it can be used on patients.
Photocrosslinkable chitosan 
hydrogel in medium
Chitosan (a natural polysaccharide produced by deacety-
lation of chitotin) hydrogel (CH) solution is very viscous, 
has both hemostatic and anti-bacterial properties, and 
accelerates healing (Ono et al 2000; Ishihara et al 2001). In 
animal experiments with rat models (Ishizuka et al 2007), 
submucosal injection of CH produced a signiﬁ  cantly thicker 
submucosal layer just after injection and reduced delayed 
bleeding in mucosal resections compared with hypertonic 
saline and HA. In addition, no cytotoxicity was revealed 
during in vitro testing using CH in human skin ﬁ  broblast, 
and endothelial and smooth muscle cells, but there is not 
yet enough reported evidence on the safety of CH when 
injected into the human body. More detailed toxicity test-
ing in appropriate animal models will be necessary prior to 
actual clinical use.
Injection solution with epinephrine
Immediate and delayed bleeding are the most frequent 
complications associated with endoscopic resections. 
Because the incidence of colorectal polypectomy bleeding 
reportedly ranges from 0.3% to 6.1% (Rosen et al 1993; 
Winawer et al 1993; Gibbs et al 1996; Thiis-Evensen et al 
1999; Citarda et al 2001), local epinephrine has been used 
to minimize mucosal bleeding due to its hemostatic effect, 
but the clinical beneﬁ  t is unclear. One retrospective study 
(Folwaczny et al 1997) reported that submucosal injection 
of dilute epinephrine appeared to offer a distinct advantage 
over the injection of only saline in preventing delayed 
colorectal polypectomy bleeding. Two prospective random-
ized comparative studies of submucosal injections with and 
without epinephrine in colorectal polypectomies (Hsieh 
et al 2001; Lee et al 2007), however, reported contrasting 
clinical outcomes, as epinephrine in the submucosal injec-
tion ﬂ  uid did not reduce the overall risk of delayed bleeding 
in either study. Immediate bleeding did occur less frequently 
in the epinephrine group than in the control group without 
epinephrine in one study (Hsieh et al 2001). However, 
immediate bleeding is generally not as serious as delayed 
bleeding because it can usually be successfully controlled 
using the endo-clip technique or electric coagulation 
methods such as hot biopsy or argon plasma coagulation 
(Parra-Blanco et al 2000; Tanaka et al 2001; Uraoka et al 
2005). Therefore, we do not use local epinephrine despite 
its microvascular hemostatic effect during EMR proce-
dures, but it cannot be avoided in ESDs particularly during 
submucosal cutting, as concomitant vasoconstrictive agent 
administration may be necessary (Soetikno et al 2003; 
Fujishiro et al 2006); however, clinical evidence is limited 
as to the efﬁ  cacy of a dilute epinephrine mixture to reduce 
immediate bleeding.Drug Design, Development and Therapy 2008:2 137
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Addition of dye to submucosal 
injection solution
A small account of indigo carmine dye can be added to the 
submucosal injection solution during the ESD procedure to 
clarify the area of submucosal injection and to distinguish 
clearly between the muscle layer and the submucosal layer.
Summary
The “ideal” submucosal injection solution should provide a 
sufﬁ  ciently high submucosal ﬂ  uid cushion for safe and effec-
tive EMRs and ESDs while also preserving specimen tissue 
for accurate histopathological lesion assessment. The various 
agents differ in terms of effectiveness, cost, and availability, 
so that the appropriate submucosal injection solution should 
be chosen on a case-by-case basis taking into account the 
location and size of the lesion, the type of procedure (EMR 
or ESD) to be performed, and the kind of electrosurgical 
knife being used during the procedure.
For instance, glycerol is now a recommended solution 
because it facilitates easier and safer colorectal EMRs. HA has 
proven to be advantageous in performing gastric ESDs using a 
standard needle knife (Yamamoto et al 1999, 2002, 2003), but 
its use may not continue for EMRs and ESDs given its high 
cost. In fact, both glycerol and NS have been reported to be 
satisfactory when performing gastric ESDs with an insulation-
tipped (IT) knife (Ohkuwa et al 2001; Ono et al 2001; Soetikno 
et al 2003; Gotoda 2005).While HA is currently indispensable 
for reducing the risk of perforation in the narrow angulated and 
thinner wall of the colorectum, we have recently been using a 
more cost-effective mixture of HA and glycerol in colorectal 
ESDs (Saito et al 2005, 2007; Uraoka et al 2007).
Finally, several high viscosity solutions, including 
HPMC, CMC, and CH, have shown promising prelimi-
nary results, but more detailed toxicity testing is needed 
on appropriate animal models and humans before any 
of them will be ready for use in clinical endoscopic 
applications.
Conclusion
Safe and effective EMRs and ESDs require the selection of 
a facilitative submucosal injection solution that also takes 
into account relevant cost-beneﬁ  t considerations. It should 
be noted, though, that successful endoscopy procedures 
also depend, in large part, on the skillful use of appropriate 
endoscopic techniques and devices.
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